• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Propeller Health Lands FDA 510(k) Clearance to Market Sensor for the Ellipta Inhaler

by Fred Pennic 11/07/2016 Leave a Comment

Propeller Health Lands FDA 510(k) Clearance to Market Digital Sensor for the Ellipta Inhaler

Propeller Health, a Madison, Wisconsin-based provider of digital solutions for respiratory medicine has received FDA 510(k) clearance to market its digital sensor for use with GSK’s Ellipta® patented, dry powder inhaler. The custom sensor designed exclusively for the Ellipta inhaler was cleared as part of a R&D collaboration between Propeller and GSK announced in late 2015.

For the R&D collaboration, the Propeller sensor automatically collected and recorded data on the Ellipta inhaler’s usage (i.e. date and time of each use), wirelessly transmitting the information to a central data repository for analysis by GSK’s clinical researchers. The sensor technology provided greater insights into adherence patterns across patient populations and may allow for more precise correlation of adherence with safety, efficacy and economic outcomes.

“While it is still in the early stages of development, the emerging field of digital healthcare holds great promise for respiratory medicine. The approval of the Propeller platform for use with the Ellipta inhaler will help us understand how patients interact with the Ellipta inhaler accurately and in real-time. By exploring the benefits of sensor technology in this way, we hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials,” said Dave Allen, head of respiratory R&D at GSK.

The Propeller Health platform has been used by patients with asthma or COPD in over 45 commercial programs across the US, including major healthcare systems, payers, employers and other commercial partners. Propeller creates a custom view of each patient, allowing them and their physicians to better understand the impact and management of their disease in daily life. This clearance marks the eighth FDA clearance, as well as the eighth international clearance, received by Propeller to date.

Propeller plans to collaborate with GSK to deploy the Propeller System and Ellipta sensor in the US and abroad.

 

Tagged With: asthma health app, Propeller Health, respiratory Apps, respiratory medicine, Smart Inhaler

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |